Abstract:Introduction: Drug repositioning is a strategy to identify a new therapeutic indication for molecules that have been approved for other conditions, aiming to speed up the traditional drug development process and reduce its costs. The high prevalence and incidence of coronavirus disease 2019 (COVID-19) underline the importance of searching for a safe and effective treatment for the disease, and drug repositioning is the most rational strategy to achieve this goal in a short period of time. Another advantage of repositioning is the fact that these compounds already have established synthetic routes, which facilitates their production at the industrial level. However, the hope for treatment cannot allow the indiscriminate use of medicines without a scientific basis. Results: The main small molecules in clinical trials being studied to be potentially repositioned to treat COVID-19 are chloroquine, hydroxychloroquine, ivermectin, favipiravir, colchicine, remdesivir, dexamethasone, nitazoxanide, azithromycin, camostat, methylprednisolone, and baricitinib. In the context of clinical tests, in general, they were carried out under the supervision of large consortiums with a methodology based on and recognized in the scientific community, factors that ensure the reliability of the data collected. From the synthetic perspective, compounds with less structural complexity have more simplified synthetic routes. Stereochemical complexity still represents the major challenge in the preparation of dexamethasone, ivermectin, and azithromycin, for instance. Conclusion: Remdesivir and baricitinib were approved for the treatment of hospitalized patients with severe COVID-19. Dexamethasone and methylprednisolone should be used with caution. Hydroxychloroquine, chloroquine, ivermectin, and azithromycin are ineffective for the treatment of the disease, and the other compounds presented uncertain results. Preclinical and clinical studies should not be analyzed alone, and their methodology's accuracy should also be considered. Regulatory agencies are responsible for analyzing the efficacy and safety of a treatment and must be respected as the competent authorities for this decision, avoiding the indiscriminate use of medicines.

Current Status of COVID-19 Therapies and Drug Repositioning Applications

Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight

Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates

Recent computational drug repositioning strategies against SARS-CoV-2.

COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery

COVID-19: molecular targets, drug repurposing and new avenues for drug discovery

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives

Repositioning of 8565 existing drugs for COVID-19

Therapeutic strategies for COVID-19: progress and lessons learned

A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19

An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment Strategies

Identification of Therapeutic Drugs Against COVID-19 Through Computational Investigation on Drug Repurposing and Structural Modification

Molecular targets in SARS-CoV-2 infection: An update on repurposed drug candidates

Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics

Identification and Development of Therapeutics for COVID-19

COVID-19 drug discovery and treatment options

Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies

Computational Drug Repositioning and Elucidation of Mechanism of Action of Compounds against SARS-CoV-2

Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action

Current status of potential therapeutic candidates for the COVID-19 crisis

Therapeutics for COVID-19 and post COVID-19 complications: An update